Stock Buzzer: Could Flexion Therapeutics Inc Change Direction After Today’s Significant Decline?

Stock Buzzer: Could Flexion Therapeutics Inc Change Direction After Today's Significant Decline?

The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) is a huge mover today! About 2.58 million shares traded hands or 830.70% up from the average. Flexion Therapeutics Inc (NASDAQ:FLXN) has risen 60.40% since April 14, 2016 and is uptrending. It has outperformed by 55.71% the S&P500.
The move comes after 5 months negative chart setup for the $493.01 million company. It was reported on Nov, 16 by Barchart.com. We have $16.47 PT which if reached, will make NASDAQ:FLXN worth $54.23 million less.

Flexion Therapeutics Inc (NASDAQ:FLXN) Ratings Coverage

Out of 7 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Flexion Therapeutics has been the topic of 7 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Wednesday, September 9 by Needham. The company was initiated on Wednesday, June 29 by BMO Capital Markets. Lake Street initiated Flexion Therapeutics Inc (NASDAQ:FLXN) on Thursday, July 21 with “Buy” rating. The firm earned “Outperform” rating on Tuesday, May 3 by Wells Fargo. As per Wednesday, November 4, the company rating was initiated by Cantor Fitzgerald.

According to Zacks Investment Research, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 2.85 in 2016 Q2. Its up 1.20, from 1.65 in 2016Q1. The ratio increased, as 9 funds sold all Flexion Therapeutics Inc shares owned while 11 reduced positions. 21 funds bought stakes while 36 increased positions. They now own 18.68 million shares or 38.37% more from 13.50 million shares in 2016Q1.
Teachers Advisors, a New York-based fund reported 29,707 shares. Ruggie Capital Gru has invested 0% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Gilder Gagnon Howe And Llc has invested 1.28% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Adage Capital Prtn Grp Incorporated Ltd Liability Company, a Massachusetts-based fund reported 76,000 shares. Morgan Stanley has invested 0% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Sabby Management Llc holds 100,800 shares or 0.08% of its portfolio. The New York-based Gru has invested 0% in Flexion Therapeutics Inc (NASDAQ:FLXN). Proshare Advisors Ltd Liability Corp accumulated 18,320 shares or 0% of the stock. The California-based Blackrock Institutional Na has invested 0% in Flexion Therapeutics Inc (NASDAQ:FLXN). Royal State Bank Of Canada has 0% invested in the company for 68,058 shares. Parametric Portfolio Assocs Ltd Liability has invested 0% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Moreover, Dupont Mgmt has 0.01% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 19,491 shares. Southport Limited accumulated 1.5% or 50,000 shares. Millennium Management Limited Liability Company holds 26,028 shares or 0% of its portfolio. Moreover, Schroder Invest Gru has 0.01% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 331,530 shares.

Insider Transactions: Since May 17, 2016, the stock had 4 buys, and 0 insider sales for $30.01 million net activity. Bodick Neil bought 800 shares worth $7,680. Clayman Michael D. also bought $19,297 worth of Flexion Therapeutics Inc (NASDAQ:FLXN) shares. $13,387 worth of Flexion Therapeutics Inc (NASDAQ:FLXN) shares were bought by MERRIFIELD C ANN. COLELLA SAMUEL D had bought 714,285 shares worth $10.00 million on Wednesday, June 8. Shares for $10.00 million were bought by LUBASH BARBARA N. DRISCOLL FREDERICK W bought $24,668 worth of Flexion Therapeutics Inc (NASDAQ:FLXN) on Tuesday, May 17. On Wednesday, June 8 the insider Versant Ventures III – LLC bought $10.00 million.

More important recent Flexion Therapeutics Inc (NASDAQ:FLXN) news were published by: Fool.com which released: “Why Shares of Flexion Therapeutics, Inc., Lantheus Holdings Inc, and PDL …” on November 16, 2016, also Globenewswire.com published article titled: “Flexion Therapeutics Announces Pricing of Public Offering of Common Stock”, Rttnews.com published: “Flexion Therapeutics Inc. (FLXN) Is Losing Ground After Offering Announcement” on November 15, 2016. More interesting news about Flexion Therapeutics Inc (NASDAQ:FLXN) was released by: Fiercebiotech.com and their article: “Flexion Therapeutics Reports Primary Endpoint Met in Pivotal Phase 3 Trial of …” with publication date: February 16, 2016.

FLXN Company Profile

Flexion Therapeutics, Inc., incorporated on November 5, 2007, is a specialty pharmaceutical company. The Firm is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain. The Company’s lead product candidate, Zilretta (also known as FX006), is a late-stage, injectable, sustained-release, intra-articular (IA) steroid for patients with moderate to severe OA pain. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Firm has not generated any revenue.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment